Kontakt
QR-Code für die aktuelle URL

Pressemitteilung Box-ID: 1086394

EvidentIQ Group GmbH Große Johannisstraße, 7 20457 Hamburg, Deutschland https://evidentiq.com
Ansprechpartner:in Herr David Renzelmann +49 89 4522775000

EvidentIQ launches eConsent, a way to meet patients where they are.

eConsent for faster recruitment and decrease of study duration

(PresseBox) ( Hamburg, )
Today EvidentIQ announced the launch of an eConsent to help improve trial participants’ experience by meeting them where they are.

Over the past years eConsent software, which helps trial participants to read and sign informed consent documents online, has exploded in popularity. Paper informed consents do not promote consistent dialogue and informed decision-making. They have become increasingly complex, technical, and more difficult for patients to understand clinical research objectives. Adding the variability in literacy levels and cultural diversity, the development of ICFs has become overly intricate and an inefficient means for conveying information about a trial to the patient. 

Studies conducted by the FDA have shown that 20% of eligible patients do not enroll due to lack of understanding regarding the study specifics and 5% of eligible patients drop out due to misunderstood expectations. At the same time, informed consent is required in most medical settings. With regards to clinical studies, the study can’t start until the document is signed, hence the importance of having an easy and fast way of having access to that. 

Considering these problems and with a willingness to bring the best solution for its customers, EvidentIQ decided to launch its own eConsent. EvidentIQ's eConsent solution offers new avenues and goes beyond what traditional eConsent solutions offer. It leverages EvidentIQs 500K+ patient community scattered across the US and Europe to accelerate enrollment in a hybrid or decentralized trial setup. 

Depending on the trial, the patient can use any connected device, review materials related to the trial, and schedule a live consultation with the study personnel to ask further questions. During that time, the patient can be seen, and the study personnel can share all media interactively and respond to any questions the patient submitted during the initial material reviews. At the end of that process, a 21 CFR Part 11 compliant eSignature can be collected, and the patient will be enrolled into the EDC system. 

To assist the subject in understanding the material, EvidentIQs eConsent uses interactive electronic-based technology, which include diagrams, images, graphics, and videos. EvidentIQs eConsent can be tailored to the intended audience, taking into consideration the subject’s age, language, and comprehension level. 

An important part of this tool is the authentication feature, which in this case is provided by a multiple layer of authentications, whether it be in the form of an OTP or an email verification. A secure solution also provides various methods of document authentication by requiring participants to upload multiple forms of identification such as a state ID, driver’s license, and/or a health card. 

EvidentIQs eConsent will help increase transparency via remote control, give the ability to focus on patient’s targeted questions and areas of concern, avoid on-site ICF versioning issues and enable DCT and Hybrid trials while reducing trial costs.  

EvidentIQ Group GmbH

EvidentIQ is a next generation technology-amplified data science group championing new standards in value creation and innovation driven relevance for customers. The EvidentIQ offering brings a pioneering end to end eClinical solution that meets increasing customer demand across clinical operations and clinical data management needs with a suite of applications within a single integrated cloud platform. By combining its platform with a broad data science service portfolio such as patient recruitment, patient engagement media and a host of RWE late phase solutions EvidentIQ significantly helps customers optimize HTA submissions, pricing and reimbursement needs.

EvidentIQ supports 15 of the top 20 pharma companies through novel RWE solutions and 150+ SMB customers in over 20 countries, including US, Germany, France, UK, Italy, Japan and China.

Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien. Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.
Wichtiger Hinweis:

Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die unn | UNITED NEWS NETWORK GmbH gestattet.

unn | UNITED NEWS NETWORK GmbH 2002–2022, Alle Rechte vorbehalten

Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien. Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.